Fast Five Quiz: Prognosis of Primary Myelofibrosis

Emmanuel C. Besa, MD


July 16, 2020

A Mayo-Careggi MPN Alliance study found that among 709 Mayo Clinic patients with PMF, 66% had a JAK2 mutation, 19% had a CALR mutation, and 5.4% had an MPL mutation. A further 10% of patients were triple-negative for these mutations.

Patients with a CALR type 1–like mutation had longer survival than those with JAK2 (hazard ratio [HR], 2.6; 95% CI, 1.9-3.5), CALR type 2–like (HR, 2.5; 95% CI 1.4-4.5), and MPL (HR, 1.8; 95% CI, 1.1-2.9) mutations and those with triple-negative mutational status (HR, 2.4; 95% CI, 1.6-3.6).

Learn more about a prognostic model for PMF that combines age and mutation status in the JAK2, CALR, and MPL genes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.